Investor Recommends Celera Spin Out Merck Royalty Asset
February 11, 2010
Investor Recommends Celera Spin Out Merck Royalty Asset
An institutional investor has suggested that the firm spin out or distribute a royalty asset tied to a Merck phase III drug.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter - UPCI Team Developing Lung Cancer Dx; Latest Entrant into Crowded, Growing Space
March 23, 2012 / ProteoMonitor - Integrated Diagnostics Secures Additional $10M to Prep for 2013 Launch of Lung Cancer Dx
February 24, 2012 / ProteoMonitor - Cepheid Terminates Roche PCR License; Reports Record Revenues in Q3 2011
October 20, 2011 / PCR Insider